Elanco announces agreement to acquire Lohmann Animal Health

Elanco, the animal health division of Eli Lilly and Company, announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines, and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco’s vaccine presence, broaden Elanco’s product offerings, and significantly augment Elanco’s vaccine manufacturing capabilities.

“Effectively competing in the animal vaccine segment is a cornerstone of Elanco’s long-term strategy and is one more way we will expand the value we create for customers,” said Jeff Simmons, senior vice president of Eli Lilly and Company and president of Elanco Animal Health. “The addition of Lohmann Animal Health provides a unique opportunity for Elanco to expand our presence in the global poultry market and to enter the global poultry vaccine market with a solid base, established products, and global commercial and manufacturing capabilities.”